Coronavirus Vaccine : Oxford’s Scientists Promises 1 Million Doses by September

ChAdOx1 technology : COVID-19 vaccine trials currently underway

London, Digital Desk : A coronavirus vaccine trial by University of Oxford researchers aims to get efficacy results by September, and manufacturing is already underway.

A team led by Sarah Gilbert, a professor of vaccinology, has recruited 500 volunteers from the ages of 18 to 55 for the early- and mid-stage randomized controlled trial. It will be extended to older adults and then to a final stage trial of 5,000 people. Gilbert said that the timing is ambitious but achievable.

We would hope to have at least some doses that are ready to be used by September . There won’t be enough for everywhere by then, but the more manufacturing we can do starting from now, then the more doses there will be ..

Sarah Gilbert

Very Strong Chance of Working

The three-phase trial will start with 510 volunteers, and as many as 5,000 are expected to join by the third phase.

The researchers believe their technology is safer than the other candidate vaccines, which will save a lot of time during the clinical trials and authorisation process.

…I have worked on this technology a lot and I have worked on MERS vaccine trails and I have seen what it can do, and I think it has a very strong chance of working,

Prof. Gilbert

Gilbert’s team was awarded a £2·2 million grant from the UK’s National Institute for Health Research and the UK Research and Innovation earlier this year to scale up its work.

The team says it is working with different groups and philanthropists to make sure the vaccine is available in places where it’s needed the most, including less-privileged countries.

Read Also : India Testing Covid-19 Vaccine

The group’s experimental immunization is among the first to enter clinical trials. The World Health Organization counts 70 vaccine candidates in development, with three others in human testing. They are from CanSino Biological Inc. and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc.; and Moderna Inc. along with the National Institute of Allergy and Infectious Diseases.

Read Also : Female World Leaders are More Active to Reduce Covid-19 Crisis

(News Source : India Today and Livemint)